Terug
Dagbereik
€ 12,51
€ 13,80
52-Weeksbereik
€ 5,68
€ 16,74
Volume
1.207.980
50D / 200D Gem.
€ 12,96
/
€ 9,43
Vorige Slotkoers
€ 12,74
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -3,5 | 0,4 |
| P/B | 1,9 | 2,9 |
| ROE % | -44,0 | 3,8 |
| Net Margin % | — | 3,9 |
| Rev Growth 5Y % | — | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Hold
€ 30,43
+137.0%
Low: € 26,00
High: € 38,00
Forward WPA
-€ 3,02
Omzet Sch.
27 M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
-€ 0,92
-€ 1,79 – € 0,01
|
280 M | 2 |
| FY2029 |
-€ 2,97
-€ 5,74 – € 0,03
|
70 M | 4 |
| FY2028 |
-€ 2,52
-€ 3,24 – -€ 1,87
|
52 M | 6 |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 24, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4.582 | € 14,47 | € 66.302 |
| Feb 24, 2026 |
AHMED NADIM
President and CEO
|
sell | 13.515 | € 14,47 | € 195.562 |
| Feb 20, 2026 |
Fenton Mary Kay
Chief Financial Officer
|
sell | 4.398 | € 13,62 | € 59.901 |
| Feb 20, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4.982 | € 13,62 | € 67.855 |
| Feb 20, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 11.742 | € 13,62 | € 165.366 |
| Feb 20, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
other | 16.000 | € 4,30 | — |
| Feb 18, 2026 |
Savill Corrine
Chief Business Officer
|
grant | 175.000 | — | — |
| Feb 18, 2026 |
Jones Jeffrey Alan
Chief Medical Officer
|
grant | 300.000 | — | — |
| Feb 18, 2026 |
Fenton Mary Kay
Chief Financial Officer
|
grant | 206.250 | — | — |
| Feb 18, 2026 |
SUMER JACQUELYN L
Chief Legal Officer
|
grant | 230.000 | — | — |
| Feb 12, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 416 | € 12,03 | € 5.004 |
| Jan 22, 2026 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 4.000 | € 12,30 | € 49.200 |
| Dec 31, 2025 |
Fenton Mary Kay
Chief Financial Officer
|
grant | 27 | € 6,49 | € 175 |
| Dec 23, 2025 |
AHMED NADIM
President and CEO
|
sell | 9.922 | € 10,01 | € 99.319 |
| Dec 19, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 1.345 | € 10,01 | € 13.463 |
| Dec 18, 2025 |
Jones Jeffrey Alan
Chief Medical Officer
|
sell | 4.632 | € 9,67 | € 44.791 |
| Dec 18, 2025 |
SUMER JACQUELYN L
Chief Legal Officer
|
sell | 3.480 | € 9,67 | € 33.652 |
| Dec 18, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 2.898 | € 9,67 | € 28.024 |
| Dec 15, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 995 | € 11,90 | € 11.841 |
| Dec 12, 2025 |
Michaelson Jennifer
Chief Scientific Officer
|
sell | 2.148 | € 12,38 | € 26.592 |
Belangrijkste Punten
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -175,80M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-44,02%
ROIC-44,05%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
0,01
Current Ratio10,25
Interest Coverage0,00
Waardering
P/E Ratio
-3,53
P/B Ratio1,90
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -219,88M |
| ROE | -44,02% | ROA | -49,04% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -175,80M |
| ROIC | -44,05% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,01 | Current Ratio | 10,25 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | -3,53 | P/B Ratio | 1,90 |
| P/S Ratio | N/A | PEG Ratio | -0,14 |
| EV/EBITDA | N/A | Dividend Yield | 0,00% |
| Market Cap | 777,16M | Enterprise Value | 691,51M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 0,0 | 0,0 | 18,94M |
| Net Income | -219,88M | -167,38M | -153,16M | 111,21M | -65,57M |
| EPS (Diluted) | -3,72 | -3,11 | -3,69 | 2,38 | -1,48 |
| Gross Profit | -311.000,0 | -306.000,0 | 0,0 | 0,0 | 18,94M |
| Operating Income | -241,65M | -196,92M | -191,09M | 144,65M | -67,95M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 448,37M | 621,82M | 484,18M | 561,12M | 437,19M |
| Total Liabilities | 39,64M | 31,50M | 30,29M | 26,09M | 11,81M |
| Shareholders' Equity | 408,73M | 590,33M | 453,70M | 535,03M | 424,97M |
| Total Debt | 2,68M | 2,15M | 3,59M | 5,19M | 0,0 |
| Cash & Equivalents | 88,33M | 83,01M | 98,43M | 156,15M | 59,77M |
| Current Assets | 386,76M | 414,67M | 480,19M | 474,47M | 296,56M |
| Current Liabilities | 37,74M | 30,65M | 28,14M | 22,50M | 11,75M |